rituximab,ibrutinib
janssen,abbvie
['rituximab', 'ibru', 'ritux']
 rituximab+ibrutinib in untreated splenic and nodal mzl. ibrutinib 2 y, 8 doses of r. n=30+15.
cr 12 mo: 53%.
pfs at 5 y: 86% and 59%.
splenic better dor.
safe and effective. #17icml 
Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.